Cerus is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The INTERCEPT Blood System, which is based on Co.'s technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Co.'s INTERCEPT Blood System is intented for use with blood components including platelets, plasma and red blood cells. Co. has received U.S. Food and Drug Administration approval for the INTERCEPT Blood System for Cryoprecipitation, which uses Co.'s plasma system to produce INTERCEPT Fibrinogen Complex for the treatment and control of bleeding. We show 56 historical shares outstanding datapoints in our CERS shares outstanding history coverage, used to compute CERS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CERS market cap history over the course of time is important for investors
interested in comparing CERS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CERS versus a peer is one thing; comparing
CERS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CERS can fluctuate over the course of history.
With this page we aim to empower investors researching CERS by allowing them to research the CERS market cap history. |
Free CERS Email Alerts:
Video: The Importance of Market Cap
